Zeneca's $1bn blockbusters
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Zeneca, the pharmaceuticals company, is poised to bring two new products to market in the next few weeks which have the potential to generate sales of up to $1bn a year.
Next week Accolate, the oral treatment for asthma, goes on sale in the crucial US market. It is the first time an oral treatment has been available outside Japan.
The company has had to employ an extra 100 salesmen to cope with the anticipated demand for a product which is more convenient than traditional inhalers.
Some analysts forecast that sales from the drug, which is already on sale in Finland and Ireland, could reach $500m.
It is the first drug which has been developed purely in the US.
Accolate may not secure blockbuster status, however, Amistar, Zeneca's revolutionary new fungicide, is set to achieve the accolade when it comes officially to market in the next few weeks.
The agrochemical division has developed Amistar using new chemistry which restricts its side effects on the vegetation it is treating.
It will be launched into a market worth around $5bn a year. Analysts forecast it could snatch more than 10 per cent of the market, making it a blockbuster in agrochemical terms.
Amistar can be used to treat anything from golf courses to bananas. A new plant to manufacture the product will be officially opened in Scotland next month. Trial production batches have already gone on sale.
Zeneca is also hoping that its agrochemicals division will receive a further boost next week when it hopes to secure Chinese approval for the development of a new paraquat production plant which is planned for Nantong, which is 200 miles north of Shanghai.
The green-field $80m investment is awaiting clearance of minor points and may be approved during a state visit from senior Chinese politicians next week.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments